Ahwan Pandey - Publications

Using polygenic risk scores to refine risk and outcomes in high-grade serous ovarian cancer in Australia.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Published: December 07, 2025

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Journal: Research square

Published: November 19, 2025

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Journal: medRxiv : the preprint server for health sciences

Published: October 03, 2025

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Journal: Nature communications

Published: September 22, 2025

Oxford Classic-Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 17, 2024

IdentifiHR predicts homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression.

Journal: Communications medicine

Published: September 19, 2024

Overcoming intra-tumoral heterogeneity for biomarker discovery in the high-grade serous ovarian cancer proteome.

Journal: NPJ precision oncology

Published: September 19, 2024

Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.

Journal: NPJ precision oncology

Published: May 06, 2024

Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.

Journal: medRxiv : the preprint server for health sciences

Published: November 21, 2023

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 14, 2023

Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer.

Journal: Nature communications

Published: November 08, 2023

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.

Journal: Scientific reports

Published: September 26, 2023